2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157461
    Glycation-IN-1 3023711-86-3 98%
    Glycation-IN-1 (Compound 3) is an inhibitor of glycosylation reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases.
    Glycation-IN-1
  • HY-157488
    α-Glucosidase-IN-46 98%
    α-Glucosidase-IN-46 is a potent α-glucosidase inhibitor with an IC50 of 26.0 μM. α-Glucosidase-IN-46 can be used for the research of type 2 diabetes.
    α-Glucosidase-IN-46
  • HY-157489
    α-Glucosidase-IN-47 3029697-33-1 98%
    α-Glucosidase-IN-47 (compound 8H) is a non-competitive α-glucosidase (α-glucosidase) inhibitor with IC50 value is 38.2 μM and Ki value is 38.2 μM. α-Glucosidase-IN-47 can be used in diabetes research..
    α-Glucosidase-IN-47
  • HY-157534
    Pancreatic lipase-IN-2 98%
    Pancreatic lipase-IN-2 (compound 7r) is a potent inhibitor of pancreatic lipase (PL), with the IC50 value of 2.67 μM, that has anti-obesity effect.
    Pancreatic lipase-IN-2
  • HY-157537
    α-Amylase-IN-5 2996821-90-8 98%
    α-Amylase-IN-5 (compound 3a) is a α-amylase inhibitor, with an IC50 of 18.8 mM.
    α-Amylase-IN-5
  • HY-157601
    HSD17B13-IN-4 98%
    HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).
    HSD17B13-IN-4
  • HY-157613
    HSD17B13-IN-5 98%
    HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).
    HSD17B13-IN-5
  • HY-157615
    HSD17B13-IN-6 2576696-34-7 98%
    HSD17B13-IN-6(Compound 475) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. HSD17B13-IN-6can be used in the research of liver diseases.
    HSD17B13-IN-6
  • HY-157632
    HSD17B13-IN-13 2762668-28-8 98%
    HSD17B13-IN-13 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-13 can be used in the research of liver diseases, such as NAFLD.
    HSD17B13-IN-13
  • HY-157650
    HSD17B13-IN-20 2919797-59-2 98%
    HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.
    HSD17B13-IN-20
  • HY-157653
    HSD17B13-IN-22 2919797-60-5 98%
    HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.
    HSD17B13-IN-22
  • HY-157654
    HSD17B13-IN-26 2919797-61-6 98%
    HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.
    HSD17B13-IN-26
  • HY-157662
    HSD17B13-IN-33 2730027-85-5 98%
    HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-33
  • HY-157663
    HSD17B13-IN-36 2730027-86-6 98%
    HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-36
  • HY-157664
    HSD17B13-IN-38 2730022-56-5 98%
    HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-38
  • HY-157665
    HSD17B13-IN-39 2730022-55-4 98%
    HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-39
  • HY-157667
    HSD17B13-IN-44 2912452-29-8 98%
    HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-44
  • HY-157671
    HSD17B13-IN-45 2912452-50-5 98%
    HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-45
  • HY-157674
    HSD17B13-IN-46 2912453-90-6 98%
    HSD17B13-IN-46 (Compound 351) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-46 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-46
  • HY-157676
    HSD17B13-IN-47 2912455-14-0 98%
    HSD17B13-IN-47 (Compound 500) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-47 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-47
Cat. No. Product Name / Synonyms Application Reactivity